Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Citius Pharmaceuticals (CTXR) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Leonard Mazur will present on September 10, 2024, at 9:00 am ET at the Lotte New York Palace Hotel and host one-on-one investor meetings.
Key business developments to be discussed include:
- FDA approval of LYMPHIR™ for cutaneous T-cell lymphoma treatment
- Merger of a subsidiary with TenX Keane, forming Citius Oncology (CTOR)
- Successful Phase 3 Pivotal Trial of Mino-Lok®, an antibiotic lock solution for catheter-related bloodstream infections
Investors can register on the conference website and join the live webcast presentation.
Citius Pharmaceuticals (CTXR) ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright, che si terrà dal 9 all'11 settembre 2024 a New York City. Il CEO Leonard Mazur presenterà il 10 settembre 2024, alle 9:00 ET presso il Lotte New York Palace Hotel e ospiterà incontri individuali con gli investitori.
Tra i principali sviluppi aziendali da discutere ci sono:
- Approvazione della FDA per LYMPHIR™ per il trattamento del linfoma cutaneo a cellule T
- Fusione di una sussidiaria con TenX Keane, formando Citius Oncology (CTOR)
- Successo della Fase 3 dello Studio Pivotal di Mino-Lok®, una soluzione antibiotica per le infezioni del flusso sanguigno correlate al catetere
Gli investitori possono registrarsi sul sito web della conferenza e partecipare alla presentazione in diretta.
Citius Pharmaceuticals (CTXR) anunció su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright del 9 al 11 de septiembre de 2024 en la ciudad de Nueva York. El CEO Leonard Mazur presentará el 10 de septiembre de 2024, a las 9:00 am ET en el Lotte New York Palace Hotel y llevará a cabo reuniones individuales con los inversores.
Los principales desarrollos empresariales a discutir incluyen:
- Aprobación de la FDA para LYMPHIR™ para el tratamiento del linfoma de células T cutáneas
- Fusión de una subsidiaria con TenX Keane, formando Citius Oncology (CTOR)
- Éxito en la Fase 3 del Estudio Pivotal de Mino-Lok®, una solución antibiótica para infecciones de sangre relacionadas con catéteres
Los inversores pueden registrarse en el sitio web de la conferencia y unirse a la presentación en webcast en vivo.
Citius Pharmaceuticals (CTXR)는 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. CEO 레너드 마저(Lenard Mazur)는 2024년 9월 10일 오전 9시 ET에 롯데 뉴욕 팰리스 호텔에서 발표를 하고 투자자들과 일대일 회의를 진행할 예정입니다.
논의될 주요 사업 개발 사항은 다음과 같습니다:
- 피부 T세포 림프종 치료를 위한 LYMPHIR™의 FDA 승인
- 자회사가 TenX Keane과 합병하여 Citius Oncology (CTOR)가 형성됨
- 카테터 관련 혈류 감염 치료를 위한 항생제 락 솔루션인 Mino-Lok®의 3상 중요 임상 시험 성공
투자자들은 컨퍼런스 웹사이트에 등록하고 라이브 웹캐스트 발표에 참여할 수 있습니다.
Citius Pharmaceuticals (CTXR) a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright, qui se déroulera du 9 au 11 septembre 2024 à New York. Le PDG Leonard Mazur présentera le 10 septembre 2024 à 9h00 ET au Lotte New York Palace Hotel et animera des réunions individuelles avec des investisseurs.
Les principaux développements commerciaux à discuter incluent :
- Approbation de la FDA pour LYMPHIR™ dans le traitement du lymphome à cellules T cutané
- Fusion d'une filiale avec TenX Keane, formant Citius Oncology (CTOR)
- Succès de l'Essai Pivotal de Phase 3 de Mino-Lok®, une solution antibiotique pour les infections sanguines liées aux cathéters
Les investisseurs peuvent s'inscrire sur le site Web de la conférence et se joindre à la présentation en direct par webdiffusion.
Citius Pharmaceuticals (CTXR) gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt, die vom 9. bis 11. September 2024 in New York City stattfinden wird. CEO Leonard Mazur wird am 10. September 2024 um 9:00 Uhr ET im Lotte New York Palace Hotel präsentieren und Einzelgespräche mit Investoren führen.
Zu den wesentlichen Geschäftsentwicklungen, die besprochen werden sollen, gehören:
- FDA-Zulassung von LYMPHIR™ zur Behandlung von kutanem T-Zell-Lymphom
- Fusion einer Tochtergesellschaft mit TenX Keane, wodurch Citius Oncology (CTOR) entsteht
- Erfolgreiche Phase-3-Pivotal-Studie von Mino-Lok®, einer antibiotischen Lock-Lösung für katheterbezogene Blutstrominfektionen
Investoren können sich auf der Konferenzwebsite registrieren und an der Live-Webcast-Präsentation teilnehmen.
- None.
- None.
CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET
H.C. Wainwright Conference Details:
Presentation: | 9:00 am ET on Tuesday, September 10, 2024* |
Location: | Lotte New York Palace Hotel, |
Registration: | Available on the conference website. |
1x1 meetings: | Requests available upon registration or by contacting Citius Investor Relations. |
Webcast: |
*Please note that the presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.
Recent Business Developments:
During his presentation and investor meetings, Mr. Mazur will discuss recent business developments including:
- FDA Approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of cutaneous T-cell lymphoma (CTCL);
- Merger of the Company's subsidiary with TenX Keane to form publicly listed Citius Oncology, Inc. (Nasdaq: CTOR); and,
- Achieving primary and secondary endpoints in the completed Phase 3 Pivotal Trial of Mino-Lok®, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns approximately
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302239745.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
When is Citius Pharmaceuticals (CTXR) presenting at the H.C. Wainwright Conference?
What recent FDA approval will Citius Pharmaceuticals (CTXR) discuss at the conference?
What is the status of Citius Pharmaceuticals' (CTXR) Mino-Lok® Phase 3 trial?
What recent merger will Citius Pharmaceuticals (CTXR) address at the H.C. Wainwright Conference?
